Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeoVax Labs (GOVX) Cash & Equivalents (2016 - 2025)

GeoVax Labs (GOVX) has disclosed Cash & Equivalents for 16 consecutive years, with $5.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 41.71% to $5.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.0 million, a 41.71% decrease, with the full-year FY2024 number at $5.5 million, down 14.66% from a year prior.
  • Cash & Equivalents was $5.0 million for Q3 2025 at GeoVax Labs, up from $3.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $34.7 million in Q3 2022 to a low of $768859.0 in Q1 2024.
  • A 5-year average of $14.3 million and a median of $12.7 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 9296.81% in 2021, then crashed 96.78% in 2024.
  • GeoVax Labs' Cash & Equivalents stood at $11.4 million in 2021, then surged by 141.71% to $27.6 million in 2022, then tumbled by 76.63% to $6.5 million in 2023, then fell by 14.66% to $5.5 million in 2024, then decreased by 9.04% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for GOVX's Cash & Equivalents are $5.0 million (Q3 2025), $3.1 million (Q2 2025), and $7.4 million (Q1 2025).